Table 1.
Factor | Recurrence | Nonrecurrence | P value |
---|---|---|---|
Sex (M/F) | 31/70 | 208/389 | .31 |
Age at diagnosis | 50.04 ± 12.60 | 51.58 ± 11.53 | .22 |
Tumor size (cm) | 2.25 ± 1.13 | 2.08 ± 1.25 | .21 |
Neurofibromatosis | .67 | ||
Yes | 2 (11.7%) | 15 (88.3%) | |
No | 77 (15.4%) | 424 (84.6%) | |
Unknown | 22 (12.2%) | 158 (87.8%) | |
Surgical approach | .12 | ||
Translabyrinthine | 18 (15.6%) | 97 (84.4%) | |
Retrosigmoid/suboccipital | 29 (13.0%) | 194 (87.0%) | |
Middle fossa | 7 (12.3%) | 50 (87.7%) | |
Unknown | 3 (60.0%) | 2 (40.0%) | |
Medical center | .43 | ||
Academic hospital | 65 (16.4%) | 332 (83.6%) | |
Private hospital | 32 (12.9%) | 217 (87.1%) | |
VA hospital | 4 (7.7%) | 48 (92.3%) | |
Treatment complicationa | .75 | ||
Present | 12 (13.0%) | 80 (87.0%) | |
Absent | 89 (14.7%) | 517 (85.3%) |
Abbreviations: M/F, male/female ratio; VA, veteran administration.
Detailed post‐treatment complications other than noted in Table 2 (ie, tinnitus, imbalance, cognitive problems, cerebrospinal fluid leak, synkinesis, headache, hydrocephalus, meningitis, and stroke) were not statistically different between the recurrence and nonrecurrence groups.